Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Managing MS: Trends, Issues, and Perspectives.
Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.
Damage to the optic chiasm in myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis mice.
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.
[New therapies in multiple sclerosis].
Journal Club: Intrathecal effects of daclizumab treatment of multiple sclerosis.
Remyelination: The True Regeneration of the Central Nervous System.
Sphingolipids in ocular inflammation.
Internet-based social networking and its role in the evolution of chronic cerebrospinal venous insufficiency.
Nrf2 in health and disease: current and future clinical implications.
Clinical Proton MR Spectroscopy in Central Nervous System Disorders.
Pediatric Acute Transverse Myelitis Overview and Differential Diagnosis.
Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
Neurocardiogenic Pulmonary Oedema: Initial Presentation of Multiple Sclerosis.
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
[The role of chronic venous insufficiency in the pathogenesis of brain diseases].
Gait variability and disability in multiple sclerosis.
Tenascins and inflammation in disorders of the nervous system.
Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis.
Interleukin-36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis.
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
Disclosing the diagnosis of multiple sclerosis: The Profile Project.
Therapeutic Armamentarium and Health System Coverage of Multiple Sclerosis in Latin America.
[Change of treatment in patients with multiple sclerosis and its consequences in clinical practice].
Cannabinoids in the management of difficult to treat pain.

Pages